Open Access

Proteomic and bioinformatic analysis of recurrent anaplastic oligodendroglioma

Contributed equally
Journal of Analytical Science and Technology20134:6

DOI: 10.1186/2093-3371-4-6

Received: 12 March 2013

Accepted: 12 March 2013

Published: 18 April 2013



Anaplastic oligodendroglioma (AO) is a type of glioma that is believed to originate from oligodendrocytes in the brain or from glial precursor cells. Recurrence of AO reduces the overall survival rate of patients and causes meningeal or even systemic spread/metastasis more frequently than other types of gliomas. We performed proteomic analysis of recurrent AO tumors to identify the proteins significantly expressed in recurrent AO and to understand biological characteristics of recurrent AO.


Using human brain tissues, we identified 401 proteins that were significantly expressed in recurrent AO. Through bioinformatic analysis, we determined that the majority of the identified proteins are involved in anti-apoptotic pathway and cell proliferation. In addition, our findings suggest that epidermal growth factor (EGF) signaling may be responsible for the development of recurrent AO.


These results will aid researchers in understanding the pathology of recurrent AO and identifying the therapeutic targets for the treatment of recurrent AO.


The goal of proteomics is a comprehensive, quantitative description of protein expression and its changes under the influence of biological perturbations such as disease or drug treatment (Anderson & Anderson 1998; Blackstock & Weir 1999). Proteins are vital parts of living organisms, as they are the main components of the physiological metabolic pathways of cells (James 1997). Recently, a number of proteomic studies have focused on the metabolic and signaling pathways associated with the formation and progression of tumors. The information obtained from proteomic analysis can be used to identify biomarkers or therapeutic targets of tumors (Alterovitz et al. 2008).

Anaplastic oligodendroglioma [AO, World Health Organization (WHO) grade III] is a type of glioma that is believed to originate from oligodendrocytes in the brain or from glial precursor cells. AO occurs primarily in adults (9.4% of all primary brain tumors), but also sometimes occurs in children (4% of all primary brain tumors) (Allison et al. 1997). AO is distinguished from other brain tumors by a unique constellation of molecular genetic alterations, including the coincident loss of chromosomal arms 1p and 19q in 50–70% of tumors (Gregory et al. 1998). AO also has a genetic profile similar to that of other primary gliomas, such as amplification of epidermal growth factor receptor (EGFR) expression, 10q loss, p16 deletion, and phosphatase and tensin homolog (PTEN) mutation without 1p loss or tumor protein 53 (TP53) mutation (Anthony et al. 2003). The standard treatment for AO is surgical resection followed by radiation and chemotherapy with procarbazine, lomustine, and vincristine (PCV) (Kyritsis et al. 1993; Allison et al. 1997; Cairncross et al. 1992; Cairncross & Macdonald 1988; Cairncross et al. 1998; Glass et al. 1992; Kleinberg et al. 1993; Mason et al. 1996). Despite high response rates (≥ 70%) to treatment, the median survival period is relatively short (Glass et al. 1992). Accumulation of diverse genetic and epigenetic alterations that occur due to interventions for treatment of the tumor may cause extensive changes in the expression of genes involved in oncogenesis leading to treatment-related effects such as aggressive transformation (Kleinberg et al. 1993).

Despite advances in the treatment and understanding of primary AO, recurrent AO is significantly less well understood. Although a recent study reported the microRNA expression profile in patients with recurrent AO (Kim et al. 2011), the biological characteristics of recurrent AO have never been studied. In this study, we conducted proteomic analysis of recurrent AO to examine protein profiles in recurrent AO and identify biological and molecular characteristics of recurrent AO.

Materials and methods

Patient samples and protein extraction

Institutional Review Board of the Catholic University of Korea approved of this study. The three specimens were obtained from patients with recurrent AO treated with total excision and adjuvant radiotherapy with total dose of 55.8 Gray (Additional file 1: Table S1) (Kim et al. 2011). The specimens were separated during surgery at the Seoul St. Mary’s Hospital and stored in liquid nitrogen at -80°C.

Protein extraction was conducted previously described (Cao & Liang 2012) with minor modification. The specimens is added to RIPA buffer (89900, Pierce Biotechnology, IL, USA) containing protease inhibitor cocktail (78410, Pierce), and sonication. Centrifuge 14,000 rpm, 4°C, 20 min, and store supernatant at -80°C. After, the supernatant was used for SDS-PAGE and LC-MS/MS.

SDS-PAGE and in-gel digestion with trypsin

Protein samples were separated by 12% SDS-PAGE (mini-PROTEAN, BIO-RAD). A 100 ug of protein sample was applied to each lane, and the gels were stained with Coomassie Brilliant Blue R-250. In-gel digestion was conducted in accordance with the previously described method (Kim et al. 2006). Gels were fractionated into 10 parts according to molecular weight. Each part was digested with trypsin (1.2 ug) for 16 hours at 37°C after reduction and alkylation of cysteines of the proteins. Digested peptides were extracted by extraction solution (50 mM ammonium bicarbonate, 50% acetonitrile, and 5% trifluoroacetic acid). Digested peptides were resolved in 10 ul of sample solution containing 0.02% formic acid and 0.5% acetic acid, and stored at -80°C until required.

LC-MS/MS analysis and protein identification

The peptide samples (5 ul) were concentrated on a Easy-column™ (L 2cm, ID 100um, 120Å, C18-A1) trapping column (PROXEON, Denmark). Peptides were eluted from the column and directed onto a Easy-column™ (L 10cm, ID 75um, 120Å, C18-A2) reversephase column (PROXEON, Denmark) at a flow rate of 200 nl/min. Peptides were eluted by a gradient of 0~65% acetonitrile for 120 min. All MS and MS/MS spectra in the LTQ-Velos ESI ion trap mass spectrometer (Thermo Scientific, USA) were acquired in a data-dependent mode. Each full MS (m/z range of 300 to 2,000) scan was followed by seven MS/MS scans of the most abundant precursor ions in the MS spectrum with dynamic exclusion enabled. For protein identification, MS/MS spectra were searched by MASCOT (Matrix science, The proteome sequence database of IPI human ver. 3.82 ( was used as the database. Mass tolerance of parent ion and fragment ion was 1.5 Da and 1.3 Da, respectively. Cabamidomethylation of cysteine and oxidation of methionine were considered in MS/MS analysis as variable modifications of tryptic peptides. Mascot score was recalculated by percolator function in the mascot for increasing sensitivity of correct identification and false discovery ratios (FDR) of the search results was adjusted to below 2%.

Bioinformatic analysis

Using Ingenuity Pathway Analysis (IPA) tool, all of the identified proteins in recurrent AO were subjected analysis of indicated metabolic and signaling pathway. The identified proteins in recurrent AO were subjected to query global protein network analysis and direct/indirect interactions on proteins that are involved in pathways associated with epidermal growth factor receptor (EGFR). For functional enrichment analysis of Gene Ontology (GO) categories, GOfact online tool ( was used. p-value of Fisher’s exact test determines the probability that the association between the proteins in the dataset and the biological function/pathways explained by chance alone.

Results and discussion

Proteomic analysis of recurrent AO

First, we performed proteomics analysis using tumor sample from patient with recurrent AO who were treated with postoperative chemoradiotherapy. From LC-MS/MS, 401 proteins were shown significantly to express in recurrent AO (Additional file 2: Table S2) and then we analyzed the 401 identified proteins using the Ingenuity Pathway Analysis (IPA) tool ( The results revealed the majority of the metabolically associated proteins that was involved in biosynthesis of carbohydrates, such as glyoxylate and dicaboxylate metabolism, oxidative phosphorylation and glycolysis/gluconeogenesis (Figure 1A). With respect to the signaling pathways active in recurrent AO, the identified proteins were associated with pathways responsible for cell growth (Figure 1B). These findings indicate that recurrent AO may be in the biological state of actively growth.
Figure 1

IPA canonical pathway analysis. Top 15 categories of metabolic pathway (A) and signaling pathway (B) were indicated. The degree of enrichment or depletion of identified proteins in a given function category is represented as -log(p-value).

Biological process of recurrent AO

To confirm the biological state of actively growth and discover the specific cause of recurrent AO, Gene Ontology (GO) annotation analysis was performed. As shown in Figure 2A, the results indicated that the identified proteins were connected to anti-apoptotic functions, while only a few were associated with glial cell apoptosis. This may indicate why recurrent AO is resistant to chemoradiotherapy. Anti-apoptotic effects often contribute to cancer cell survival and chemoresistance in cancer cells (Williams et al. 2005). The 18 proteins that are involved in anti-apoptosis pathways are listed in Additional file 1: Table S3.
Figure 2

Analysis of biological processes of recurrent AO using Gene Ontology (GO) annotation. (A) Distribution of anti-apoptosis and glial cell apoptosis in recurrent AO. (B) Distribution of cell proliferation, cell adhesion, cell migration and cell differentiation in recurrent AO. The degree of enrichment or depletion of identified proteins in a given function category is represented as -log(p-value).

Multiple biological processes, including cell proliferation, adhesion, and migration, have been shown to be involved in tumor development (Lee 1992). Base on our analyses, the 14 proteins appear to be linked to cell proliferation processes (Figure 2B). Fourteen of these proteins are presented in Additional file 1: Table S4. Tumor cell is related to cell adhesion and motility. Cell motility is necessary to moves within tissues during invasion and metastasis by their own motility (Ymazaki et al. 2005; Zang et al. 2006). The 11 proteins and 9 proteins appear to be linked to cell adhesion and migration, respectively (Additional file 1: Table S5 and Table S6). These findings indicate that the expression of proteins related to anti-apoptotic and cell proliferation pathways are closely related to the development of recurrent AO. Understanding the functions of these proteins in recurrent AO would contribute to the development of therapeutics for the prevention or treatment of this disease.

Signaling pathways associated with tumor development in recurrent AO

Recent studies claimed that growth factor signaling is involved in tumorigenesis and the development of malignancy (Lee 2001). EGF signaling is well known to be involved in the autonomous growth of cancer cells (Normanno et al. 2001), and FGF signaling plays a pivotal role in cancer development (Cao et al. 2011). Wnt and Notch signaling are also associated with tumor development (Allenspach et al. 2002; Paul 2000). Therefore, we investigate whether the identified proteins is involved in various signaling pathway. The results showed that EGF signaling is highly associated with recurrent AO compared to other signaling pathways (Figure 3). This is in agreement with a previous report showing that amplification of EGFR, which permits evasion of cancer cell death, has been observed in cases of recurrent AO that develop resistance to treatment (Paul 2000). Additionally, Wnt and Notch signaling were also associated with recurrent AO. Further studies regarding the role of Wnt and Notch signaling during the development of AO recurrence will be necessary.
Figure 3

Distribution of signaling pathway associated with cancer. Gene Ontology (GO)-determined signaling pathways associated with cancer. The degree of enrichment or depletion of identified proteins in a given function category is represented as -log(p-value).

Proteins related to EGFR in recurrent AO

Based on the fact that EGF signaling is highly related to recurrent AO (Figure 3) and activation of EGFR is responsible for the resistance of recurrent AO to treatment, novel regulators or effectors that mediate EGFR signaling in recurrent AO were sought. EGFR signaling plays roles in cell proliferation, angiogenesis, and inhibition of apoptosis processes that are essential for cancer development (Normanno et al. 2001). By additional bioinformatics analysis of the identified proteins identified using IPA tool, we indeed found that 15 proteins are closely associated with EGFR (Figure 4 and Additional file 1: Table S7), implying that these proteins may play an important role in the development of recurrent AO.
Figure 4

Proteins related to EGFR in recurrent AO. IPA-determined network of identified proteins in the recurrent AO that may be involved in EGFR signaling. Dotted line, indirect; Solid line, direct.


In this study, we identified proteins significantly expressed in recurrent AO. Extensive bioinformatics analysis revealed that these proteins are involved in biological processes and signaling pathways that are associated with the development of recurrent AO. Cells in recurrent AO are highly resistant to apoptosis and actively proliferating. Analysis of signaling pathway enrichment also showed that EGF signaling is active in recurrent AO. This is the first analysis to identify and characterize the proteins associated with recurrent AO. Further studies, investigating the role of these identified proteins in recurrent AO will contribute to a more thorough understanding of the molecular mechanisms that mediate the development of this disease.




This work was supported by Seoul St. Mary’s Clinical Medicine Research Program year of 2009 and the Catholic Medical Center Research Foundation year of 2010 through the Catholic University of Korea, Korea Basic Science Institute (T32414), and the Pioneer Research Center Program of the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012-0000432).

Authors’ Affiliations

Division of Life Science, Korea Basic Science Institute
Pioneer Research Center for Protein Network Exploration, Korea Basic Science Institute
Department of Functional Genomics, University of Science and Technology (UST)
Department of Radiation Oncology, Ajou University School of Medicine
Department of Radiation Oncology, Seoul St. Mary’s Hospital, The Catholic University of Korea


  1. Allenspach EJ, Maillard I, Aster C, Warren S: Notch Signaling in Cancer. Cancer Biol Ther 2002, 5: 466–476.View ArticleGoogle Scholar
  2. Allison RR, Schulsinger A, Vongtama V: Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol Biol Phys 1997, 37: 399–403. 10.1016/S0360-3016(96)00452-XView ArticleGoogle Scholar
  3. Alterovitz G, Xiang M, Liu J, Chang MF: System-wide peripheral biomarker discovery using information theory. P.S.biocomuting 2008, 13: 231–242.Google Scholar
  4. Anderson NL, Anderson NG: Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 1998, 19: 1853–1861. 10.1002/elps.1150191103View ArticleGoogle Scholar
  5. Anthony B, Khe HX, Antoine FC, Delattre JV: Primary brain tumours in adults. Lancet 2003, 361: 323–31. 10.1016/S0140-6736(03)12328-8View ArticleGoogle Scholar
  6. Blackstock WP, Weir MP: Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol 1999, 17: 121–127. 10.1016/S0167-7799(98)01245-1View ArticleGoogle Scholar
  7. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988, 23: 360–364. 10.1002/ana.410230408View ArticleGoogle Scholar
  8. Cairncross JG, Macdonald DR, Ramsay DA: Aggressive oligodendroglioma: A chemosensitive tumor. Neurosurgery 1992, 31: 78–82. 10.1227/00006123-199207000-00011View ArticleGoogle Scholar
  9. Cairncross JG, Ueki K, Zlatescu MC: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90: 1473–1479. 10.1093/jnci/90.19.1473View ArticleGoogle Scholar
  10. Cao R, Liang S: Liver plasma membranes: an effective method to analyze membrane proteome. Methods Mol Biol 2012, 909: 113–123.Google Scholar
  11. Cao XM, Meng HS, Hong F, Ying QS: Fibroblast Growth Factor Receptor 4 Regulates Proliferation and Antiapoptosis During Gastric Cancer Progression. Cancer 2011, 1: 5340–5313.Google Scholar
  12. Glass J, Hochberg FH, Gruber ML: The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 1992, 76: 741–745. 10.3171/jns.1992.76.5.0741View ArticleGoogle Scholar
  13. Gregory J, Keisuke U, Magdelena CZ, David KL: Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas. J Natl Cancer Inst 1998, 90: 1473–1479. 10.1093/jnci/90.19.1473View ArticleGoogle Scholar
  14. James P: Protein identification in the post-genome era: the rapid rise of proteomics. Q Rev Biophys 1997, 30: 279–331. 10.1017/S0033583597003399View ArticleGoogle Scholar
  15. Kim YH, Cho K, Yun SH, Kim JY, Kwon KH, Yoo JS, Kim SI: Analysis of aromatic catabolic pathways in Pseudomonas putida KT 2440 using a combined proteomic approach: 2-DE/MS and cleavable isotope-coded affinity tag analysis. Proteomics 2006, 6: 1301–1318. 10.1002/pmic.200500329View ArticleGoogle Scholar
  16. Kim G, Park EC, Chung HR, Jeon SS, Kim SI, Jang HS, Kim GH, Choi BO: MicroRNA expression profiling in recurrent anaplastic oligodendroglioma treated with postoperative radiotherapy. JAST 2011, 2: 97–104. 10.5355/JAST.2011.97View ArticleGoogle Scholar
  17. Kleinberg L, Wallner K, Malkin MG: Good performance status of long-term disease-free survivors of intracranial gliomas. Int J Radiat Oncol Biol Phys 1993, 26: 129–133. 10.1016/0360-3016(93)90183-VView ArticleGoogle Scholar
  18. Kyritsis AP, Yung WK, Bruner J: The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993, 32: 365–370. 10.1227/00006123-199303000-00005View ArticleGoogle Scholar
  19. Lee AS: Mammalian stress response: induction of the glucose-regulated protein family. Curr Opin Cell Biol 1992, 4: 267–273. 10.1016/0955-0674(92)90042-BView ArticleGoogle Scholar
  20. Lee AS: The glucose-regulated proteins: stress induction and clinical application. Trends Biochem Sci 2001, 26: 504–511. 10.1016/S0968-0004(01)01908-9View ArticleGoogle Scholar
  21. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996, 46: 203–207. 10.1212/WNL.46.1.203View ArticleGoogle Scholar
  22. Normanno N, Bianco C, De Luca A, Salomon DS: The role of EGF related peptides in tumor growth. Front Biosci 2001, 6: d685-d707. 10.2741/NormanoView ArticleGoogle Scholar
  23. Paul P: Wnt signaling and cancer. Genes Dev 2000, 14: 1837–1851.Google Scholar
  24. Williams J, Lucas PC, Griffith KA: Expression of BclxL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005, 96: 287–295. 10.1016/j.ygyno.2004.10.026View ArticleGoogle Scholar
  25. Ymazaki D, Kurisu S, Takenawa T: Regulation of cancer cell motility through actin reorganization. Cancer Sci 2005, 96: 379–386. 10.1111/j.1349-7006.2005.00062.xView ArticleGoogle Scholar
  26. Zang XP, Bullen EC, Manjeshwar S, Jupe ER, Howard EW, Pneto JT: Enhanced motility of KGF-transfected breast cancer cells. Anticancer reseatch 2006, 26: 961–966.Google Scholar


© Hong et al.; licensee Springer. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.